Diagnostics firm Biomerica's Q1 revenue drops on lower clinical lab orders

Biomerica

16/10/2026 13:30

Overview
Biomedical diagnostics firm's fiscal Q1 revenue declined yr/yr due to lower clinical lab orders
Company posted net loss for fiscal Q1, compared to breakeven a year earlier
Operating expenses fell 14% yr/yr as company focused on cost discipline

Outlook
Company expects continued expansion of Medicare billing and physician adoption for inFoods IBS
Future CDM revenue will depend on progress and scope of work under current development agreement
Company is evaluating strategic opportunities, including partnerships and business combinations

Result Drivers
OTC SALES - Co said 81% increase in over-the-counter sales in Q1 was mainly driven by sales to a new customer
CLINICAL LAB ORDERS - Co attributed Q1 revenue decline to lower clinical laboratory customer orders and shipment timing
CONTRACT MANUFACTURING - Co said ongoing contract development and manufacturing projects contributed to revenue in Q1

Company press release: ID:nGNX6LY6Yb

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
 
$1.3 mln
 
Q1 Loss Per Share
 
$0.37
 
Q1 Net Loss
 
$1.2 mln
 
Q1 Gross Margin
 
8.00%
 
Q1 Operating Expenses
 
$1.3 mln
 
Q1 Operating Income
 
-$1.2 mln
 

Reuters Recommended Reads
Oct 14 - Bank of America third-quarter profit falls on $1.2-billion fine

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)